Please login to the form below

Not currently logged in
Email:
Password:

UK court backs Actavis in dispute over Lilly's Alimta

Actavis’ generic version ruled not to infringe Lilly’s intellectual property

Eli Lilly

Eli Lilly has suffered a setback in its efforts to prevent generic competition to its big-selling lung cancer treatment Alimta.

The UK High Court has ruled that a patent held by Lilly on a vitamin regimen for Alimta (pemetrexed disodium) - a series of vitamin B12 injections used to reduce the drug's side effects - is not infringed by a generic version of the drug sold by Allergan's Actavis unit.

Lilly has said it will seek permission to appeal the verdict as it tries to defend one of its biggest brands from generic competition in Europe.

Specifically, the High Court has concluded that Actavis' pemetrexed trometamol product - a different salt form of the drug which is sold in the UK, France, Italy and Spain with instructions to dilute the product only with dextrose solution - does not infringe Lilly's intellectual property.

That follows a Court of Appeal decision last June, which held that if Actavis were to market its product with instructions to dilute the drug in saline it would infringe the vitamin regimen patent. That court did not however deliver a verdict on whether an alternative salt form with instructions to dilute only in dextrose solution would infringe.

Alimta is used to treat non-squamous non-small cell lung cancer (NSCLC) and was Lilly's second-biggest product last year - bringing in almost $2.5bn - although sales have started to decline in the face of reduced demand as well as competition and reduced pricing.

The compound patent on pemetrexed disodium expired in December 2015 in most European markets, but Lilly has endeavoured to protect its franchise with the vitamin patent, which extends to June 2021.

Last year, the validity of Lilly's vitamin regimen patent was upheld by a prior European Patent Office (EPO) ruling; an appeal against that decision was upheld towards the end of 2015.

In addition to the UK setback, Lilly's efforts to block Alimta generics also stumbled in Germany last year, after the Dusseldorf Court of Appeal ruled the Alimta vitamin regimen patent would not be infringed by yet another salt - Actavis' pemetrexed dipotassium - after the December 2015 compound patent expiration.

Now however Lilly says it has been granted leave to appeal that ruling in the Federal Supreme Court in Germany and expects that case to be heard later this year. The company says it has also been granted an injunction against another would-be competitor in Germany.

Maintaining Alimta's revenue stream is a priority for Lilly as it weathers the loss of patent protection for other brands, including osteoporosis drug Evista (raloxifene) and antidepressant Cymbalta (duloxetine) and brings new products through its late-stage pipeline and onto the market.

The company has high hopes for oral rheumatoid arthritis candidate baricitinib - just filed in the US - and recently-approved NSCLC therapy Portrazza (necitumumab).

Article by
Phil Taylor

15th February 2016

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....